Laboratory screening fort side effects of disease modifying antirheumatic drugs in daily rheumatological practice

Scandinavian Journal of Rheumatology

Volumn 27, Issue 3, 1998, Pages 170-179

  Simon, C H ^a   Vliet Vlieland, Th P M ^a   Dijkmans, B A C ^a   Bernelot Moens, H J ^a   Janssen, M ^a   Hazes, J M W ^a   Franken, H C M ^a   Vandenbroucke, J P ^a   Breedveld, F C ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Disease modifying antirheumatic drugs; Laboratory tests; Screening; Side effects

Indexed keywords

ANTIMALARIAL AGENT; ANTIRHEUMATIC AGENT; AZATHIOPRINE; GOLD; METHOTREXATE; PENICILLAMINE; SALAZOSULFAPYRIDINE;

ADULT; AGED; ARTICLE; BLOOD EXAMINATION; CREATININE BLOOD LEVEL; DRUG SURVEILLANCE PROGRAM; FEMALE; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; LABORATORY TEST; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SCREENING TEST; ADOLESCENT; CLINICAL PRACTICE; CLINICAL TRIAL; COHORT ANALYSIS; DIAGNOSIS, MEASUREMENT AND ANALYSIS; DRUG MONITORING; MIDDLE AGED; MULTICENTER STUDY; RETROSPECTIVE STUDY; RHEUMATOLOGY; STANDARD; STATISTICS;

ADOLESCENT; ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; AGED; AGED, 80 AND OVER; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COHORT STUDIES; DRUG MONITORING; FEMALE; HUMANS; LABORATORY TECHNIQUES AND PROCEDURES; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; RETROSPECTIVE STUDIES; RHEUMATOLOGY;

EID: 0031615765     PISSN: 03009742     EISSN: None     Source Type: Journal    
DOI: 10.1080/030097498440778     Document Type: Article

References (26)

1. Ad Hoc Committee on Clinical Guidelines of the ACR. Guidelines for the management of rheumatoid arthritis. Arthritis Rheum 1996;39:713-22.
2. ten Wolde S, Breedveld FC, Hermans J, et al. Randomised placebo-controlled study of stopping second-line drugs in rheumatoid arthritis. Lancet 1996;347:347-52.
3. Singh G, Fries JF, Williams CA, Zatarain E, Spitz P, Bloch DA. Toxicity profiles of disease modifying antirheumatic drugs in rheumatoid arthritis. J Rheumatol 1991;18:188-94.
4. Fries JF, Williams CA, Ramey D, Bloch DA. The relative toxicity of disease-modifying antirheumatic drugs. Arthritis Rheum 1993;36:297-306.
5. Cervi PL, Wright P, Casey EB. Audit of full blood count monitoring in patients on longterm gold therapy for rheumatoid arthritis. Ir J Med Sci 1992;161:73-4.
6. Comer M, Scott DL, Doyle DV, Huskisson EC, Hopkins A. Are slow-acting anti-rheumatic drugs monitored too often? An audit of current clinical practice. Br J Rheumatol 1995;34:966-70.
7. Kay EA, Pullar T. Variations among rheumatologists in prescribing and monitoring of disease modifying antirheumatoid drugs. Br J Rheumatol 1992;31:477-83.
8. Prashker MJ, Meenan RF. The total costs of drug therapy for rheumatoid arthritis. A model based on costs of drug, monitoring, and toxicity. Arthritis Rheum 1995;38:318-25.
9. Simon CH, Dijkmans BAC, Breedveld FC. Variations in the monitoring and management of the side effects of antirheumatic drugs by means of laboratory tests. Clin Exp Rheumatol 1997;15:633-9.
10. Arnett FC, Edworthy SM, Bloch DA, et al. The American rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
11. Rynes RI. Antimalarial drugs. In: Kelly WN, Harris ED, Ruddy S, Sledge CB, eds. Textbook of Rheumatology. Philadelphia: WB Saunders Company, 1993:731-42.
12. Gordon DA. Gold compounds in the rheumatic diseases. In: Kelly WN, Harris ED, Ruddy S, Sledge CB, eds. Textbook of Rheumatology. Philadelphia: WB Saunders Company, 1993:743-59.
13. Jaffe IA. Penicillamine. In: Kelly WN, Harris ED, Ruddy S, Sledge CB, eds. Textbook of Rheumatology. Philadelphia: WB Saunders Company, 1993:760-6.
14. Day RO. Sulfasalazine. In: Kelly WN, Harris ED, Ruddy S, Sledge CB, eds. Textbook of Rheumatology. Philadelphia: WB Saunders Company, 1993:692-9.
15. Weinblatt ME. Methotrexate. In: Kelly WN, Harris ED, Ruddy S, Sledge CB, eds. Textbook of Rheumatology. Philadelphia: W. B. Saunders Company, 1993:767-78.
16. Fauci AS, Randall Young K. Immunoregulatory agents. In: Kelly WN, Harris ED, Ruddy S, Sledge CB, eds. Textbook of Rheumatology. Philadelphia: WB Saunders Company, 1993:797-821.
17. Runge LA. Antimalarials. In: McCarty DJ, Koopman WJ, eds. Arthritis and allied conditions. Malvern: Lea & Febiger, 1993:615-9.
18. Skosey JL. Gold compounds and d-penicillamine. In: McCarty DJ, Koopman WJ, eds. Arthritis and allied conditions. Malvern: Lea & Febiger, 1993:603-14.
19. Clegg DO. Sulfasalazine. In: McCarty DJ, Koopman WJ, eds. Arthritis and allied conditions. Malvern: Lea & Febiger, 1993:637-43.
20. Rooney TW, Furst DE. Methotrexate. In: McCarty DJ, Koopman WJ, eds. Arthritis and allied conditions. Malvern: Lea & Febiger, 1993:621-36.
21. Cannon GW, Ward JR. Cytotoxic drugs and combination drug therapy. In: McCarty DJ, Koopman WJ, eds. Arthritis and allied conditions. Malvern: Lea & Febiger, 1993:645-63.
22. Day RO. SAARDs-I. In: Klippel JH, Dieppe PA, eds. Rheumatology. London: Mosby-Year Book Europe Limited, 1994;12:1-10.
23. Furst DE, Clements PJ. SAARDs-II. In: Klippel JH, Dieppe PA, eds. Rheumatology. London: Mosby Year Book Europe Limited, 1994;13:1-8.
24. Kay A. Monitoring of slow-acting remission-inducing (SARI) drugs. Br J Rheumatol 1989;28:239-41.
25. Kremer JM, Alarcon GS, Lightfoot RW Jr, et al. Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. American College of Rheumatology. Arthritis Rheum 1994;37:316-28.
26. Ad Hoc Committee on Clinical Guidelines of the ACR. Guidelines for monitoring drug therapy in rheumatoid arthritis. Arthritis Rheum 1996;39:723-31.